Table II.

Selected clinical trials in OC that use vaccines, adoptive cell transfers or oncolytic viruses.

Clinical trial approach	Clinical trial	# OC patients	Objective responses	Reference or Trial ID
Vaccines	Phase II trial of recombinant vaccinia and fowlpox vaccines expressing NY-ESO-1, 2012	22	21 mos PFS 4 year OS	90
	Phase II trial of subcutaneous p53 peptide vaccination, 2012	13	4.2 mos PFS 41 mos OS	92
	Phase I trial of p53-synthetic long peptide vaccine, 2012	20	No increase in OS	93
Adoptive Cell Transfers	Phase II trial of p53-pulsed dendritic cells vaccine, 2012	6	8.7 mos PFS 29.6 mos OS	92
	Phase I/II vaccination trial of Her2/neu, telomerase, and PADRE peptide-pulsed DCs ± cyclophosphamide, 2012	11	90% 3 year OS NED in 6 pts at 3 yrs	99
	Phase I trial of autologous tumor lysate-pulsed dendritic cells + bevacizumab, cyclophosphamide, and autologous tumor lysate-primed T cells, 2013	6	2 – PR 2 – SD 2 - PD	100
	Pilot study of MUC1-primed cytotoxic T lymphocyte transfer, 2012	7	1 – CR 6 - PD	105
	Phase I trial of anti-mesothelin CAR T cells, ongoing	N/A	N/A	NCT02159716
	Phase I trial of anti-mesothelin CAR T cells + chemotherapy, ongoing	N/A	N/A	NCT01583686
	Phase I trial of anti-VEGFR2 CD8+ CAR T cells + chemotherapy, ongoing	N/A	N/A	NCT01218867
Oncolytic viruses	Phase I trial of CA-125- or Na/I symporter-expressing measles virus, ongoing	N/A	N/A	NCT00408590
	Phase I/II trial of Na/I symporter-expressing measles virus infected mesenchymal stem cells, ongoing	N/A	N/A	NCT02068794
	Phase II trial of thymidine kinase-inactivated vaccinia virus, ongoing	N/A	N/A	NCT02017678
	Phase I/II trial of oncolytic adenovirus, ongoing	N/A	N/A	NCT02028117
	Phase II trial of oncolytic reovirus, ongoing	N/A	N/A	NCT02028117

Abbreviations: PD, progressive disease; IR, initial response; CR, complete response; CCR, continued clinical response; PR, partial response; SD, stable disease; NED, no evidence of disease; NR, no response; N/A, not available; PFS, progression-free survival; OS, overall survival.